SecBot SecBot

CVKD drug pipeline

$1.83
+30.7% 1-day · Nov 17
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.6%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
3
2 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2 completed; pivotal Phase 3 planned (FDA End-of-Phase 2 meeting concluded)
Time to marketPhase 3 not yet started; company projects NDA submission in 2029, implying potential approval no earlier than ~2030 if the pivotal trial succeeds.

CAD-1005 Updated Aug 20

What to watch

Watch for (1) the start/enrollment of the planned 120-patient pivotal Phase 3 trial in HIT, (2) any outcome of the announced partnering process to out-license or co-develop CAD-1005, and (3) financing news, year-end cash of ~$4M was flagged as insufficient to fund Phase 3, and a July 2026 $3M placement already diluted shareholders by ~33%, so another raise is likely before any 2029 NDA. The stock trades near its 52-week low (~$1.66 vs a $14.64 high), and the only near-term analyst action on record is an HC Wainwright Buy maintain; treat the analyst mean target of $14 as far-dated optionality, not a near-term signal.

Bull case
  • Positive Phase 2 result: >25% absolute reduction in thrombotic events in HIT, presented at ISTH 2026 (8-K/analysis and press-release summaries in local data).
  • Regulatory momentum: FDA Fast Track and Orphan Drug designations for HIT, plus completed End-of-Phase 2 meeting with a defined pivotal Phase 3 path, a 120-patient randomized placebo-controlled trial described as the first of its kind in HIT.
  • Wall Street is constructive: consensus shows 5 Buy + 2 Strong Buy vs 1 Hold and 0 Sell; the 3-analyst price-target snapshot shows mean $14 / high $17 (implied upside ~683% vs the snapshot's $1.87 reference price), with HC Wainwright maintaining Buy in April 2026.
Bear case
  • No revenue and thin cash: ~$4.0M cash at year-end 2025 with a $3.0M quarterly net loss, and management explicitly flagged that cash may not support planned Phase 3 development.
  • Heavy dilution already underway: a July 2026 $3M H.C. Wainwright private placement (960,000 shares plus warrants for up to ~$5.8M more) was assessed as ~33% dilutive at a ~$9M market cap; further raises are likely before any 2029 NDA.
  • Binary is far away: the pivotal Phase 3 has not even started, and the NDA submission is projected for 2029, no dated regulatory catalyst (PDUFA/readout) within the next 12 months.
◆ mixed
Impact
PhasePhase 3-ready (per company disclosure); no active Phase 2/3 ClinicalTrials.gov record for tecarfarin found in ingested d
Time to marketUnknown, likely several years if at all: the company calls tecarfarin "Phase 3-ready," but no pivotal-trial start or NDA timeline was identified, and a Kawasaki-disease approval would require a partner-funded registrational program plus FDA review. No revenue exists to self-fund it.

tecarfarin Updated Aug 20

What to watch

Watch for (1) FDA action on the tecarfarin RPDD request for Kawasaki disease and (2) any definitive out-licensing/co-development agreement (an Item 1.01 8-K) from the partnering process Cadrenal opened on July 21, 2026, either could re-rate this ~$6M micro-cap. Absent those, tecarfarin alone carries no near-term catalyst, and the share price (~$1.65 vs a $14.64 52-week high) already reflects a crashed valuation with dilution overhang from the July placement and effective S-3 shelf.

Bull case
  • Rare-disease optionality: RPDD for tecarfarin in Kawasaki disease, if granted and the drug is approved, qualifies for a Priority Review Voucher reportedly valued at $180M–$205M, far above Cadrenal's ~$6M market cap (June 18, 2026 release + 8-K analysis).
  • The July 21, 2026 8-K shows tecarfarin is a Phase 3-ready asset inside a formal partnering process (out-license, monetize, or co-develop) that could bring non-dilutive capital to a cash-constrained company.
  • Street support: latest consensus shows 5 Buy + 2 Strong Buy (1 Hold) and a mean analyst price target of $14 (high $17, low $12) versus a ~$1.6–1.9 share price, per local analyst snapshot of Aug 16, 2026, though targets likely predate the current price collapse.
Bear case
  • No dated binary: the RPDD filing was only announced (not granted), no pivotal trial or PDUFA is scheduled in available data, so tecarfarin offers no hard near-term catalyst; RPDD is a designation, not approval.
  • Cash/dilution risk: no revenue, ~$4.0M cash at year-end 2025, a $3M July 2026 private placement (up to $8.8M with warrants) that analysis pegs at ~33% dilution, and an S-3 shelf effective July 20, 2026, tecarfarin development is likely contingent on financing or a partner.
● neutral
Impact
PhasePhase 2-ready (trial not yet initiated; no frunexian trial found in available ClinicalTrials.gov data)
Time to marketUnknown — Phase 2 has not started; if a trial began today, any approval would still be multiple years away, and the company is actively seeking a partner to take the asset forward.

frunexian Updated Aug 20

What to watch

Frunexian alone is not a tradeable binary, it has no scheduled catalyst, no trial data, and an undisclosed mechanism, so any near-term CVKD move is driven by the company-wide partnering process and financing events, not by this drug. Watch for an Item 1.01 8-K announcing a definitive deal or a new Phase 2 registration on ClinicalTrials.gov; treat the ~$14 mean price target (3 analysts, ~690% implied upside) skeptically, and expect dilution risk given the ~33%-dilutive July placement, effective S-3 shelf, and insider selling.

Bull case
  • Partnering optionality: the July 21, 2026 8-K formally opens an out-licensing/monetization/co-development process for frunexian and its sibling assets, a potential non-dilutive deal for a company with ~$6M market cap (exact snapshot: $6,476,057) and no current revenue.
  • Analyst support: local consensus shows buy 5 / hold 1 / strongBuy 2 (no sells), and a 3-analyst price-target snapshot shows targetMean $14 (high $17, low $12) against a ~$1.65 stock, with implied upside of 690.3% in the local snapshot (its stored currentPrice was $1.87).
  • Phase 2-ready positioning gives frunexian a distinct niche, pre-operative safety in cardiac surgery, separate from the HIT (CAD-1005) and orphan (tecarfarin) programs, adding portfolio optionality to the franchise pitch.
Bear case
  • No data, no trial, no catalyst: frunexian has no registered clinical trial, no efficacy/safety data, and its mechanism is not described in available sources, it is entirely unproven, and a Phase 2-start is undated.
  • Severe financing constraints: Cadrenal has no revenue or approved products, and in July 2026 it raised $3M via an H.C. Wainwright private placement of 960,000 shares plus warrants (potentially ~$5.8M more), estimated to dilute ~33%, extending cash runway only into Q1 2027; an S-3 shelf (File No. 333-297432) became effective July 20, 2026, adding dilution overhang.
  • Insider selling and a locally computed bearish evidence checklist: CEO/Chairman Pham Quang X sold shares repeatedly May–June 2026 under a 10b5-1 plan, and the 90-day bull/bear tool returned netSignal 'bearish' (insider sells, multiple institutional near-exits/trims, and one high short-volume-ratio session at 0.536).

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Aug 13, 2026CAD-1005Fast Track+1.6%−13.6%
Aug 13, 2026CAD-1005Orphan drug designation+1.6%−13.6%